JP2020533383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533383A5 JP2020533383A5 JP2020515148A JP2020515148A JP2020533383A5 JP 2020533383 A5 JP2020533383 A5 JP 2020533383A5 JP 2020515148 A JP2020515148 A JP 2020515148A JP 2020515148 A JP2020515148 A JP 2020515148A JP 2020533383 A5 JP2020533383 A5 JP 2020533383A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- combination drug
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 229940000425 combination drugs Drugs 0.000 claims 9
- 102000025417 antigen binding proteins Human genes 0.000 claims 6
- 108091000829 antigen binding proteins Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000003110 anti-inflammatory Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 3
- 150000003949 imides Chemical class 0.000 claims 3
- 230000002519 immonomodulatory Effects 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- 101700027111 3SA0 Proteins 0.000 claims 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 101700067609 ctx Proteins 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
Claims (11)
- 抗ＢＣＭＡ抗原結合タンパク質、免疫調節イミド薬（ＩＭｉＤ）、および場合により抗炎症化合物を含んでなる、癌の治療において使用するための組合せ医薬。
- 前記抗ＢＣＭＡ抗原結合タンパク質が、配列番号１に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＨ１；配列番号２に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＨ２；配列番号３に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＨ３；配列番号４に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＬ１；配列番号５に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＬ２；および配列番号６に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなるＣＤＲＬ３を含んでなる、請求項１に記載の組合せ医薬。
- 前記抗ＢＣＭＡ抗原結合タンパク質が、配列番号７に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなる重鎖可変領域（ＶＨ）；および配列番号８に示されるアミノ酸配列と少なくとも９０％の配列同一性を有するアミノ酸配列を含んでなる軽鎖可変領域（ＶＬ）を含んでなる抗体である、請求項１または２に記載の組合せ医薬。
- 場合により含まれる前記抗炎症化合物がデキサメタゾンである、請求項１〜３のいずれか一項に記載の組合せ医薬。
- 前記ＩＭｉＤがサリドマイド類似体である、請求項１〜４のいずれか一項に記載の組合せ医薬。
- 前記ＩＭｉＤがポマリドミドである、請求項１〜４のいずれか一項に記載の組合せ医薬。
- 前記ＩＭｉＤがレナリドミドである、請求項１〜４のいずれか一項に記載の組合せ医薬。
- 前記抗ＢＣＭＡ抗原結合タンパク質が、ＭＭＡＥまたはＭＭＡＦから選択される細胞毒素に結合された抗体を含んでなる免疫複合体である、請求項１〜７のいずれか一項に記載の組合せ医薬。
- 前記癌が、多発性骨髄腫、慢性リンパ球性白血病および非ホジキンリンパ腫から選択される、請求項１〜８のいずれか一項に記載の組合せ医薬。
- 癌の治療において使用するための医薬の製造における、抗ＢＣＭＡ抗原結合タンパク質、免疫調節イミド薬（ＩＭｉＤ）、および場合により抗炎症化合物を含んでなる組合せの使用。
- （ｉ）抗ＢＣＭＡ抗原結合タンパク質；
（ｉｉ）免疫調節イミド薬（ＩＭｉＤ）および場合により抗炎症化合物と組み合わせた場合に癌の治療において使用するための説明書
を含んでなる、癌の治療において使用するためのキット。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120208A JP2023139179A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558593P | 2017-09-14 | 2017-09-14 | |
| US62/558,593 | 2017-09-14 | ||
| PCT/IB2018/056968 WO2019053612A1 (en) | 2017-09-14 | 2018-09-12 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120208A Division JP2023139179A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533383A JP2020533383A (ja) | 2020-11-19 |
| JP2020533383A5 true JP2020533383A5 (ja) | 2021-10-21 |
Family
ID=63713945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515148A Pending JP2020533383A (ja) | 2017-09-14 | 2018-09-12 | 癌の組合せ治療 |
| JP2023120208A Pending JP2023139179A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120208A Pending JP2023139179A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200254093A1 (ja) |
| EP (1) | EP3691682A1 (ja) |
| JP (2) | JP2020533383A (ja) |
| CN (1) | CN111107874A (ja) |
| BR (1) | BR112020005077A2 (ja) |
| CA (1) | CA3075716A1 (ja) |
| WO (1) | WO2019053612A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114502593A (zh) * | 2019-08-06 | 2022-05-13 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物药物组合物和相关方法 |
| WO2021067546A1 (en) * | 2019-10-04 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof |
| CN114057890A (zh) * | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
| CA3233953A1 (en) * | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| EP0963200B9 (en) | 1996-11-05 | 2005-11-30 | The Children's Medical Center Corporation | Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7230012B2 (en) | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| PT3351240T (pt) | 2009-05-19 | 2019-06-21 | Celgene Corp | Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolino-1,3-diona |
| LT3415531T (lt) * | 2011-05-27 | 2023-09-25 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) – surišantys baltymai |
| UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP3689383A1 (en) | 2012-04-11 | 2020-08-05 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US10189906B2 (en) | 2012-11-01 | 2019-01-29 | Max-Delrück-Centrum Für Molekulare Medizin | Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| EP2953972B1 (en) | 2013-02-05 | 2020-07-08 | EngMab Sàrl | Method for the selection of antibodies against bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| CA2956002C (en) | 2014-07-24 | 2023-06-27 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| RS61781B1 (sr) | 2014-12-05 | 2021-06-30 | Memorial Sloan Kettering Cancer Center | Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe |
| TWI787645B (zh) * | 2015-04-13 | 2022-12-21 | 美商輝瑞股份有限公司 | Ｃｄ３特異性抗體、治療性雙特異性抗體及其用途 |
| PT3331910T (pt) | 2015-08-03 | 2020-03-24 | Engmab Sarl | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano |
| EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
| IL310031A (en) * | 2017-05-01 | 2024-03-01 | Juno Therapeutics Inc | A combination of cellular therapy and an immune modulatory compound |
| GB201710620D0 (en) * | 2017-07-03 | 2017-08-16 | Glaxosmithkline Intellectual Property Ltd | Targeted protein degradation |
-
2018
- 2018-09-12 EP EP18779781.6A patent/EP3691682A1/en active Pending
- 2018-09-12 US US16/646,875 patent/US20200254093A1/en not_active Abandoned
- 2018-09-12 BR BR112020005077-6A patent/BR112020005077A2/pt unknown
- 2018-09-12 CN CN201880060035.0A patent/CN111107874A/zh active Pending
- 2018-09-12 JP JP2020515148A patent/JP2020533383A/ja active Pending
- 2018-09-12 CA CA3075716A patent/CA3075716A1/en active Pending
- 2018-09-12 WO PCT/IB2018/056968 patent/WO2019053612A1/en unknown
-
2023
- 2023-07-24 JP JP2023120208A patent/JP2023139179A/ja active Pending
- 2023-08-22 US US18/453,404 patent/US20240009307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533383A5 (ja) | ||
| JP2020500538A5 (ja) | ||
| JP2020533382A5 (ja) | ||
| JP2015514110A5 (ja) | ||
| JP2017528476A5 (ja) | ||
| JP2020508303A5 (ja) | ||
| JP2021191763A5 (ja) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2017533694A5 (ja) | ||
| JP2017535257A5 (ja) | ||
| JP2018505177A5 (ja) | ||
| JP2018508483A5 (ja) | ||
| JP2017176174A5 (ja) | ||
| JP2018507220A5 (ja) | ||
| RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
| JP2017113019A5 (ja) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2019506841A5 (ja) | ||
| JP2017534577A5 (ja) | ||
| JP2016507470A5 (ja) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2015534579A5 (ja) | ||
| JP2014520088A5 (ja) | ||
| JP2010536384A5 (ja) | ||
| JP2009521496A5 (ja) |